AstraZeneca Results Presentation Deck

Core profit and loss Total revenue - product sales - collaboration revenue Gross margin Operating expenses - R&D expenses - SG&A expenses Other operating income Operating profit Tax rate EPS Impact of pandemic vaccine Q1 2021 $m 7,320 7,257 63 74.6% 4,136 1,638 2,399 1,180 2,524 8.1% 1.63 $(0.03) change % 11 11 42 (3.0) pp 11 18 7 146 34 53 % total revenue 100 99 1 57 22 33 16 34 Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales. 21 B

View entire presentation